In vivo experiments showed that mice treated with CD38/LMP1 TanCAR-T cells had smaller tumor burdens than those treated with single-target CAR-T cells, highlighting the potential of TanCAR-T cell therapy for NKTCL (40). This evidence concerns the gene CD38 and neoplasm.